Seven Mile Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Seven Mile Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$320K	Sell	644 -37	-5%	-$16.4K	0.21%	105
2026 Q1	$304K	Sell	681 -97	-12%	-$45.2K	0.22%	96
2025 Q4	$353K	Sell	778 -4	-0.5%	-$1.72K	0.06%	146
2025 Q3	$306K	Buy	782 +70	+10%	+$29.3K	0.05%	199
2025 Q2	$317K	Buy	712 +3	+0.4%	+$1.38K	0.19%	112
2025 Q1	$344K	Buy	709 +23	+3%	+$10.7K	0.23%	95
2024 Q4	$276K	Buy	686 +9	+1%	+$4.17K	0.18%	109
2024 Q3	$315K	Buy	677 +35	+5%	+$16.8K	0.21%	97
2024 Q2	$301K	Buy	642 +33	+5%	+$14.3K	0.22%	91
2024 Q1	$255K	Buy	609 +5	+0.8%	+$2.11K	0.19%	116
2023 Q4	$246K	Sell	604 -1	-0.2%	-$369	0.21%	109
2023 Q3	$210K	Buy	605 +7	+1%	+$2.45K	0.22%	109
2023 Q2	$210K	Buy	+598	New	+$201K	0.25%	97

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Seven Mile Advisory's VRTX Position: Q2 2026 in Review

Seven Mile Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, selling an estimated $16.4K and leaving 644 shares worth $320K. The position accounts for 0.21% of the portfolio, ranked #105.

Seven Mile Advisory first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $353K in Q4 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Seven Mile Advisory held 644 shares of Vertex Pharmaceuticals worth $320K as of Q2 2026.
Seven Mile Advisory sold 37 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.4K.
Vertex Pharmaceuticals made up 0.21% of Seven Mile Advisory's portfolio in Q2 2026, its #105 holding.
Seven Mile Advisory first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Seven Mile Advisory's Vertex Pharmaceuticals position peaked at $353K in Q4 2025.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Seven Mile Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.